Haemonetics Co. (NYSE:HAE - Free Report) - Investment analysts at Zacks Research lowered their FY2025 EPS estimates for shares of Haemonetics in a research note issued on Monday, February 17th. Zacks Research analyst R. Department now forecasts that the medical instruments supplier will earn $4.56 per share for the year, down from their prior forecast of $4.58. The consensus estimate for Haemonetics' current full-year earnings is $4.55 per share. Zacks Research also issued estimates for Haemonetics' Q4 2025 earnings at $1.23 EPS, Q1 2026 earnings at $1.13 EPS, Q2 2026 earnings at $1.24 EPS, Q4 2026 earnings at $1.36 EPS, FY2026 earnings at $5.06 EPS, Q1 2027 earnings at $1.39 EPS, Q2 2027 earnings at $1.47 EPS and FY2027 earnings at $5.83 EPS.
Haemonetics (NYSE:HAE - Get Free Report) last released its earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share for the quarter, missing analysts' consensus estimates of $1.20 by ($0.01). Haemonetics had a return on equity of 23.66% and a net margin of 9.47%.
A number of other equities analysts have also recently issued reports on the stock. Needham & Company LLC dropped their price objective on shares of Haemonetics from $112.00 to $108.00 and set a "buy" rating for the company in a research note on Friday, February 7th. JPMorgan Chase & Co. began coverage on shares of Haemonetics in a research report on Friday, December 6th. They issued an "overweight" rating and a $116.00 price target for the company. Bank of America downgraded Haemonetics from a "neutral" rating to an "underperform" rating and decreased their price objective for the company from $95.00 to $68.00 in a report on Friday, February 7th. Barrington Research dropped their target price on Haemonetics from $108.00 to $95.00 and set an "outperform" rating for the company in a report on Friday, February 7th. Finally, StockNews.com cut Haemonetics from a "buy" rating to a "hold" rating in a research report on Saturday, February 15th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $101.67.
Read Our Latest Research Report on HAE
Haemonetics Stock Performance
Shares of NYSE HAE traded down $0.47 during trading hours on Wednesday, reaching $62.98. The stock had a trading volume of 807,650 shares, compared to its average volume of 1,020,757. Haemonetics has a twelve month low of $58.80 and a twelve month high of $97.97. The company has a debt-to-equity ratio of 1.35, a current ratio of 3.97 and a quick ratio of 2.55. The business's fifty day moving average is $72.61 and its two-hundred day moving average is $76.66. The company has a market cap of $3.16 billion, a price-to-earnings ratio of 24.79, a PEG ratio of 1.11 and a beta of 0.39.
Institutional Investors Weigh In On Haemonetics
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Vise Technologies Inc. increased its holdings in shares of Haemonetics by 8.7% in the fourth quarter. Vise Technologies Inc. now owns 2,825 shares of the medical instruments supplier's stock valued at $221,000 after purchasing an additional 225 shares in the last quarter. Waverly Advisors LLC increased its stake in shares of Haemonetics by 17.0% in the 4th quarter. Waverly Advisors LLC now owns 12,769 shares of the medical instruments supplier's stock valued at $997,000 after buying an additional 1,857 shares during the period. Silvercrest Asset Management Group LLC raised its position in shares of Haemonetics by 31.0% during the fourth quarter. Silvercrest Asset Management Group LLC now owns 643,227 shares of the medical instruments supplier's stock worth $50,223,000 after acquiring an additional 152,042 shares during the last quarter. ProShare Advisors LLC lifted its stake in shares of Haemonetics by 40.7% during the fourth quarter. ProShare Advisors LLC now owns 16,486 shares of the medical instruments supplier's stock valued at $1,287,000 after acquiring an additional 4,771 shares during the period. Finally, Nomura Holdings Inc. bought a new position in Haemonetics in the fourth quarter valued at about $519,000. Institutional investors and hedge funds own 99.67% of the company's stock.
Haemonetics Company Profile
(
Get Free Report)
Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.
Further Reading
Before you consider Haemonetics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Haemonetics wasn't on the list.
While Haemonetics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
